|
1
|
Lowe KA, Chia VM, Taylor A, O'Malley C,
Kelsh M, Mohamed M, Mowat FS and Goff B: An international
assessment of ovarian cancer incidence and mortality. Gynecol
Oncol. 130:107–114. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reid BM, Permuth JB and Sellers TA:
Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matulonis UA, Sood AK, Fallowfield L,
Howitt BE, Sehouli J and Karlan BY: Ovarian cancer. Nat Rev Dis
Primers. 2:160612016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li T and Cho WC: MicroRNAs: Mechanisms,
functions and progress. Genomics Proteomics Bioinformatics.
10:237–238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
7
|
Hua M, Qin Y, Sheng M, Cui X, Chen W,
Zhong J, Yan J and Chen Y: miR145 suppresses ovarian cancer
progression via modulation of cell growth and invasion by targeting
CCND2 and E2F3. Mol Med Rep. 19:3575–3583. 2019.PubMed/NCBI
|
|
8
|
Xu L, Li H, Su L, Lu Q and Liu Z:
MicroRNA455 inhibits cell proliferation and invasion of epithelial
ovarian cancer by directly targeting Notch1. Mol Med Rep.
16:9777–9785. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Phatak P, Burrows WM, Chesnick IE,
Tulapurkar ME, Rao JN, Turner DJ, Hamburger AW, Wang JY and Donahue
JM: MiR-199a-3p decreases esophageal cancer cell proliferation by
targeting p21 activated kinase 4. Oncotarget. 9:28391–28407. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu J, Liu B, Guo Y, Chen Z, Sun W, Gao W,
Wu H and Wang Y: MiR-199a-3p acts as a tumor suppressor in clear
cell renal cell carcinoma. Pathol Res Pract. 214:806–813. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guan J, Liu Z, Xiao M, Hao F, Wang C, Chen
Y, Lu Y and Liang J: MicroRNA-199a-3p inhibits tumorigenesis of
hepatocellular carcinoma cells by targeting ZHX1/PUMA signal. Am J
Transl Res. 9:2457–2465. 2017.PubMed/NCBI
|
|
12
|
Cui Y, Wu F, Tian D, Wang T, Lu T, Huang
X, Zhang P and Qin L: miR-199a-3p enhances cisplatin sensitivity of
ovarian cancer cells by targeting ITGB8. Oncol Rep. 39:1649–1657.
2018.PubMed/NCBI
|
|
13
|
Deng Y, Zhao F, Hui L, Li X, Zhang D, Lin
W, Chen Z and Ning Y: Suppressing miR-199a-3p by promoter
methylation contributes to tumor aggressiveness and cisplatin
resistance of ovarian cancer through promoting DDR1 expression. J
Ovarian Res. 10:502017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu Z and Chen J: Introduction of WHO
classification of tumours of female reproductive organs, fourth
edition. Zhonghua Bing Li Xue Za Zhi. 43:649–650. 2014.(In
Chinese). PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang MY, Lin J and Kui YC: MicroRNA-345
suppresses cell invasion and migration in non-small cell lung
cancer by directly targeting YAP1. Eur Rev Med Pharmacol Sci.
23:2436–2443. 2019.PubMed/NCBI
|
|
17
|
Prat J; FIGO Committee on Gynecologic
Oncology, : Staging classification for cancer of the ovary,
fallopian tube, and peritoneum. Int J Gynaecol Obstet. 124:1–5.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu QD, Zhou QQ, Dong L, Huang Z, Wu F and
Deng X: MiR-199a-5p inhibits the growth and metastasis of
colorectal cancer cells by targeting ROCK1. Technol Cancer Res
Treat. 17:15330346187755092018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ghosh A, Dasgupta D, Ghosh A, Roychoudhury
S, Kumar D, Gorain M, Butti R, Datta S, Agarwal S, Gupta S, et al:
MiRNA199a-3p suppresses tumor growth, migration, invasion and
angiogenesis in hepatocellular carcinoma by targeting VEGFA,
VEGFR1, VEGFR2, HGF and MMP2. Cell Death Dis. 8:e27062017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fornari F, Milazzo M, Chieco P, Negrini M,
Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L and Gramantieri
L: MiR-199a-3p regulates mTOR and c-Met to influence the
doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res.
70:5184–5193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kinose Y, Sawada K, Nakamura K, Sawada I,
Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi
H, et al: The hypoxia-related microRNA miR-199a-3p displays tumor
suppressor functions in ovarian carcinoma. Oncotarget.
6:11342–11356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kroh EM, Parkin RK, Mitchell PS and Tewari
M: Analysis of circulating microRNA biomarkers in plasma and serum
using quantitative reverse transcription-PCR (qRT-PCR). Methods.
50:298–301. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen Y, Gao DY and Huang L: In vivo
delivery of miRNAs for cancer therapy: Challenges and strategies.
Adv Drug Deliv Rev. 81:128–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Häusler SF, Keller A, Chandran PA, Ziegler
K, Zipp K, Heuer S, Krockenberger M, Engel JB, Hönig A, Scheffler
M, et al: Whole blood-derived miRNA profiles as potential new tools
for ovarian cancer screening. Br J Cancer. 103:693–700. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kan CW, Hahn MA, Gard GB, Maidens J, Huh
JY, Marsh DJ and Howell VM: Elevated levels of circulating
microRNA-200 family members correlate with serous epithelial
ovarian cancer. BMC Cancer. 12:6272012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chai C, Song LJ, Yang B, Han SY, Li XQ and
Li M: Circulating miR-199a-3p in plasma and its potential
diagnostic and prognostic value in glioma. Eur Rev Med Pharmacol.
20:4885–4890. 2016.
|
|
27
|
Nonaka R, Nishimura J, Kagawa Y, Osawa H,
Hasegawa J, Murata K, Okamura S, Ota H, Uemura M, Hata T, et al:
Circulating miR-199a-3p as a novel serum biomarker for colorectal
cancer. Oncol Rep. 32:2354–2358. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Z, Liu P, Zhou X, Wang T, Feng X, Sun
YP, Xiong Y, Yuan HX and Guan KL: Endothelin promotes colorectal
tumorigenesis by activating YAP/TAZ. Cancer Res. 77:2413–2423.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li N, Yu N, Wang J, Xi H, Lu W, Xu H, Deng
M, Zheng G and Liu H: miR-222/VGLL4/YAP-TEAD1 regulatory loop
promotes proliferation and invasion of gastric cancer cells. Am J
Cancer Res. 5:1158–1168. 2015.PubMed/NCBI
|
|
30
|
Shao DD, Xue W, Krall EB, Bhutkar A,
Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, et
al: KRAS and YAP1 converge to regulate EMT and tumor survival.
Cell. 158:171–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee KW, Lee SS, Kim SB, Sohn BH, Lee HS,
Jang HJ, Park YY, Kopetz S, Kim SS, Oh SC and Lee JS: Significant
association of oncogene YAP1 with poor prognosis and cetuximab
resistance in colorectal cancer patients. Clin Cancer Res.
21:357–364. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu R, Huang S, Lei Y, Zhang T, Wang K,
Liu B, Nice EC, Xiang R, Xie K, Li J and Huang C: FGF8 promotes
colorectal cancer growth and metastasis by activating YAP1.
Oncotarget. 6:935–952. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sun D, Li X, He Y, Li W, Wang Y, Wang H,
Jiang S and Xin Y: YAP1 enhances cell proliferation, migration, and
invasion of gastric cancer in vitro and in vivo. Oncotarget.
7:81062–81076. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou Y, Yang R and Ma G: YAP1 knockdown
suppresses the proliferation, migration and invasion of human
nasopharyngeal carcinoma cells. Nan Fang Yi Ke Da Xue Xue Bao.
39:286–291. 2019.(In Chinese). PubMed/NCBI
|
|
35
|
Jeong W, Kim SB, Sohn BH, Park YY, Park
ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DSL, et al:
Activation of YAP1 is associated with poor prognosis and response
to taxanes in ovarian cancer. Anticancer Res. 34:811–817.
2014.PubMed/NCBI
|
|
36
|
Cho SY, Kim K, Park MS, Jang MY, Choi YH,
Han S, Shin HM, Chung C, Han HY, Yang JB, et al: Expression of
Yes-associated protein 1 and its clinical significance in ovarian
serous cystadenocarcinoma. Oncol Rep. 37:2620–2632. 2017.
View Article : Google Scholar : PubMed/NCBI
|
